|Payment & Shipping Terms ||Supply Capacity |
|Payment Terms:||L/C, T/T, WU||Production Capacity:||300kg/year|
|Min. Order:||200 Gram||Packing:||As per request of...|
|Means of Transport:||Ocean, Air, Land||Delivery Date:||within 7 days|
TICAGRELOR CAS 274693-27-5
icagrelor is a new kind of antiplatelet aggregation drug
Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high quality evidence for the use of ticagrelor in non-ST elevation acute coronary syndrome.The FDA indication for ticagrelor is reduction of the rate of cardiovascular death, myocardial infarction (MI), and stroke in people with acute coronary syndrome or history of myocardial infarction.
AHA/ACC Guidelines (09/2014) state: "It is reasonable to choose ticagrelor over clopidogrel for P2Y12 inhibition treatment in patients with NSTE-ACS treated with early invasive strategy and/or coronary stenting".
Ticagrelor was found to be comparable to acetylsalicylic acid in people with acute ischemic stroke or transient ischemic attack.
Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine. The substance has low solubility and low permeability under the Biopharmaceutics Classification System.
Category: Heart And Cerebral Vessels API
Related Category: Customized Pharmaceutical API
Other Pharmaceutical API
Veterinary Medicine API
Diagnostic Agents API
Vitamin Preparation API